Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is poised for success with its promising drug pipeline and strategic collaborations. The potential for FDA approval for vopimetostat in 2026 and the possibility of moving into first-line treatment ahead of a competitor's drug positions TNGX to capture a significant market share in the treatment of pancreatic and glioblastoma cancers. With a strong management team and promising preclinical data, the company has the potential to continue growing and delivering precision medicine for the treatment of cancer.

Bears say

Tango Therapeutics is likely to face challenges in the near future due to its heavy reliance on its pipeline products, particularly its PRMT5 and CoREST inhibitors. These products are still in the early stages of development and have not yet shown significant clinical success. Additionally, competition from other biotech companies, such as AZN, may hinder Tango's progress in the market. Combined with ongoing financial losses and the need for additional fundraising, it is likely that Tango's stock price will continue to be negatively affected in the short term.

Tango Therapeutics (TNGX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 10 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.